Literature DB >> 15710847

Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies.

Chester A Mathis1, William E Klunk, Julie C Price, Steven T DeKosky.   

Abstract

Advances in neuroimaging over the past 2 decades are products of breakthroughs in imaging technology, developments of more powerful computers and image-processing software, and expanding knowledge in basic and clinical neuroscience. In addition to the insights into normal brain structure and function that such methods provide and the information that can be gained from disease-related changes in structure and function, the promise of achieving diagnostic specificity through neuroimaging lies with the potential identification of pathognomonic proteins. Recent advances in imaging beta-amyloid plaques, one of the hallmarks of Alzheimer disease, offer such a technological breakthrough and the possibility for more efficient assessment of antiamyloid interventions as well as specific noninvasive diagnostic capabilities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710847     DOI: 10.1001/archneur.62.2.196

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  19 in total

1.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates.

Authors:  Karin A Stephenson; Rajesh Chandra; Zhi-Ping Zhuang; Catherine Hou; Shunichi Oya; Mei-Ping Kung; Hank F Kung
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

3.  Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.

Authors:  Yun Zhou; Susan M Resnick; Weiguo Ye; Hong Fan; Daniel P Holt; William E Klunk; Chester A Mathis; Robert Dannals; Dean F Wong
Journal:  Neuroimage       Date:  2007-03-16       Impact factor: 6.556

Review 4.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

Review 5.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

6.  Large size fibrillar bundles of the Alzheimer amyloid beta-protein.

Authors:  Rita Carrotta; Jennifer Barthès; Alessandro Longo; Vincenzo Martorana; Mauro Manno; Giuseppe Portale; Pier Luigi San Biagio
Journal:  Eur Biophys J       Date:  2007-05-11       Impact factor: 1.733

Review 7.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 8.  Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Authors:  G Brent Irvine; Omar M El-Agnaf; Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

9.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

10.  Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Authors:  Katsutoshi Furukawa; Nobuyuki Okamura; Manabu Tashiro; Masaaki Waragai; Shozo Furumoto; Ren Iwata; Kazuhiko Yanai; Yukitsuka Kudo; Hiroyuki Arai
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.